Last reviewed · How we verify
Vasopressors
Vasopressors is a Small molecule drug developed by Chulalongkorn University. It is currently in Phase 1 development. Also known as: Norepinephrine, Dopamine, Milrinone, Dobutamine.
Vasopressors are agents that raise blood pressure by constricting blood vessels, thereby increasing systemic vascular resistance. They are used to manage mean arterial pressure during cardiopulmonary bypass in cardiac surgery, among other conditions such as noncardiac surgery and anesthesia.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vasopressors |
|---|---|
| Also known as | Norepinephrine, Dopamine, Milrinone, Dobutamine, phenylephrine |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Early Methylene Blue in the Microhemodynamics of Septic Patients (PHASE2, PHASE3)
- Canadian Critical Care Comparative Effectiveness Platform (PHASE3)
- "Effect of Pre-Spinal Mindfulness-Based Breathing Exercise on Hemodynamic Response in Elective Cesarean Section" (NA)
- Time to Lose the Weight? Comparison of Weight-based and Non-weight-based Vasopressors for Septic Shock
- Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial (NA)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressors CI brief — competitive landscape report
- Vasopressors updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI
Frequently asked questions about Vasopressors
What is Vasopressors?
Who makes Vasopressors?
Is Vasopressors also known as anything else?
What development phase is Vasopressors in?
Related
- Manufacturer: Chulalongkorn University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Norepinephrine, Dopamine, Milrinone, Dobutamine, phenylephrine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing